Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β

Experimental Neurology

Volumn 261, Issue , 2014, Pages 720-732

  Muñoz, Ana ^a,b   Garrido Gil, Pablo ^a,b   Dominguez Meijide, Antonio ^a,b   Labandeira Garcia, Jose L ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Angiogenesis; Candesartan; Dopamine; Dyskinesia; Levodopa; Neuroinflammation; Parkinson; Renin angiotensin system; VEGF

Indexed keywords

ANGIOTENSIN II; BENSERAZIDE; CANDESARTAN; INTERLEUKIN 1BETA; LEVODOPA; OXIDOPAMINE; VASCULOTROPIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; VASCULOTROPIN A;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; CYLINDER TEST; DENERVATION; DOPAMINERGIC DENERVATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSKINESIA; FEMALE; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBSTANTIA NIGRA; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; IN VITRO STUDY; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; TOXICITY;

ADRENERGIC AGENTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIPARKINSON AGENTS; BENZIMIDAZOLES; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; IN VITRO TECHNIQUES; INTERLEUKIN-1BETA; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908333878     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.08.019     Document Type: Article

References (105)

1. Argaw A.T., Zhang Y., Snyder B.J., Zhao M.L., Kopp N., Lee S.C., Raine C.S., Brosnan C.F., John G.R. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J. Immunol. 2006, 177:5574-5584.
2. Aron Badin R., Spinnewyn B., Gaillard M.C., Jan C., Malgorn C., Van Camp N., Dolle F., Guillermier M., Boulet S., Bertrand A., Savasta M., Auguet M., Brouillet E., Chabrier P.E., Hantraye P. IRC-082451, a novel multitargeting molecule, reduces l-DOPA-induced dyskinesias in MPTP Parkinsonian primates. PLoS ONE 2013, 8:e52680.
3. Barcia C., Bautista V., Sanchez-Bahillo A., Fernandez-Villalba E., Faucheux B., Poza y Poza M., Fernandez Barreiro A., Hirsch E.C., Herrero M.T. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J. Neural Transm. 2005, 112:1237-1248.
4. Barnum C.J., Eskow K.L., Dupre K., Blandino P., Deak T., Bishop C. Exogenous corticosterone reduces l-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience 2008, 156:30-41.
5. Basu S., Nagy J.A., Pal S., Vasile E., Eckelhoefer I.A., Bliss V.S., Manseau E.J., Dasgupta P.S., Dvorak H.F., Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 2001, 7:569-574.
6. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2001, 2:577-588.
7. Borrajo A., Rodriguez-Perez A.I., Diaz-Ruiz C., Guerra M.J., Labandeira-Garcia J.L. Microglial TNF-alpha mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia 2014, 62:145-157.
8. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
9. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., Cenci M.A. Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 2006, 96:1718-1727.
10. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
11. Cenci M.A., Konradi C. Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog. Brain Res. 2010, 183:209-233.
12. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
13. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat. Rev. Neurosci. 2002, 3:574-579.
14. Cerovic M., Bagetta V., Pendolino V., Ghiglieri V., Fasano S., Morella I., Hardingham N., Heuer A., Papale A., Marchisella F., Giampa C., Calabresi P., Picconi B., Brambilla R. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in l-DOPA-induced dyskinesia. Biol. Psychiatry 2014, 10.1016/j.biopsych.2014.04.002.
15. Desai Bradaric B., Patel A., Schneider J.A., Carvey P.M., Hendey B. Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J. Neural Transm. 2012, 119:59-71.
16. Dominguez-Meijide A., Villar-Cheda B., Garrido-Gil P., Sierrra-Paredes G., Guerra M.J., Labandeira-Garcia J.L. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA. Neuropharmacology 2014, 76(Pt A):156-168.
17. Fasano S., Bezard E., D'Antoni A., Francardo V., Indrigo M., Qin L., Dovero S., Cerovic M., Cenci M.A., Brambilla R. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopa-induced dyskinesia. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21824-21829.
18. Faucheux B.A., Bonnet A.M., Agid Y., Hirsch E.C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999, 353:981-982.
19. Feliers D., Gorin Y., Ghosh-Choudhury G., Abboud H.E., Kasinath B.S. Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species. Am. J. Physiol. Renal Physiol. 2006, 290:F927-F936.
20. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
21. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
22. Fieblinger T., Sebastianutto I., Alcacer C., Bimpisidis Z., Maslava N., Sandberg S., Engblom D., Cenci M.A. Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J. Neurosci. 2014, 34:4728-4740.
23. Fleegal-DeMotta M.A., Doghu S., Banks W.A. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J. Cereb. Blood Flow Metab. 2009, 29:640-647.
24. Fukumoto M., Takai S., Ishizaki E., Sugiyama T., Oku H., Jin D., Sakaguchi M., Sakonjo H., Ikeda T., Miyazaki M. Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr. Eye Res. 2008, 33:885-891.
25. Garrido-Gil P., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J. Neuroinflammation 2012, 9:38.
26. Garrido-Gil P., Rodriguez-Pallares J., Dominguez-Meijide A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells. Exp. Neurol. 2013, 250:384-396.
27. Gildea J.J. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr. Opin. Nephrol. Hypertens. 2009, 18:28-32.
28. Gohlke P., Von Kugelgen S., Jurgensen T., Kox T., Rascher W., Culman J., Unger T. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J. Hypertens. 2002, 20:909-918.
29. Grover S., Kumar P., Singh K., Vikram V., Budhiraja R.D. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)-alpha and gamma agonist against a rat model of oral dyskinesia. Pharmacol. Biochem. Behav. 2013, 111:17-23.
30. Heiman M., Heilbut A., Francardo V., Kulicke R., Fenster R.J., Kolaczyk E.D., Mesirov J.P., Surmeier D.J., Cenci M.A., Greengard P. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:4578-4583.
31. Herr D., Rodewald M., Fraser H.M., Hack G., Konrad R., Kreienberg R., Wulff C. Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol. Oncol. 2008, 109:418-425.
32. Herrero M.T., Augood S.J., Asensi H., Hirsch E.C., Agid Y., Obeso J.A., Emson P.C. Effects of l-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Brain Res. Mol. Brain Res. 1996, 42:149-155.
33. Hoogwerf B.J. Renin-angiotensin system blockade and cardiovascular and renal protection. Am. J. Cardiol. 2010, 105:30A-35A.
34. Imanishi T., Hano T., Nishio I. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens. Res. 2004, 27:101-108.
35. Joglar B., Rodriguez-Pallares J., Rodriguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 2009, 109:656-669.
36. Jung Y.D., Liu W., Reinmuth N., Ahmad S.A., Fan F., Gallick G.E., Ellis L.M. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 2001, 4:155-162.
37. Kang Y.S., Park Y.G., Kim B.K., Han S.Y., Jee Y.H., Han K.H., Lee M.H., Song H.K., Cha D.R., Kang S.W., Han D.S. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J. Mol. Endocrinol. 2006, 36:377-388.
38. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation. J. Neurochem. 2001, 76:1346-1353.
39. Khan F., Spicarova Z., Zelenin S., Holtback U., Scott L., Aperia A. Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am. J. Physiol. Renal Physiol. 2008, 295:F1110-F1116.
40. Konradi C., Westin J.E., Carta M., Eaton M.E., Kuter K., Dekundy A., Lundblad M., Cenci M.A. Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis. 2004, 17:219-236.
41. Kucuk M., Kaya M., Kalayci R., Cimen V., Kudat H., Arican N., Elmas I., Korkut F. Effects of losartan on the blood-brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats. Life Sci. 2002, 71:937-946.
42. Labandeira-Garcia J.L., Rodriguez-Pallares J., Rodriguez-Perez A.I., Garrido-Gil P., Villar-Cheda B., Valenzuela R., Guerra M.J. Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease. Am. J. Neurodegener. Dis. 2012, 1:226-244.
43. Labandeira-Garcia J.L., Rodriguez-Pallares J., Dominguez-Meijide A., Valenzuela R., Villar-Cheda B., Rodriguez-Perez A.I. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. Mov. Disord. 2013, 28:1337-1342.
44. Lau S.T., Leung P.S. Role of the RAS in pancreatic cancer. Curr. Cancer Drug Targets 2011, 11:412-420.
45. Lee H.J., Han Y.M., Kim E.H., Kim Y.J., Hahm K.B. A possible involvement of Nrf2-mediated heme oxygenase-1 up-regulation in protective effect of the proton pump inhibitor pantoprazole against indomethacin-induced gastric damage in rats. BMC Gastroenterol. 2012, 12:143.
46. Li J., Huang J., Dai L., Yu D., Chen Q., Zhang X., Dai K. miR-146a, an IL-1beta responsive miRNA, induces vascular endothelial growth factor and chondrocyte apoptosis by targeting Smad4. Arthritis Res. Ther. 2012, 14:R75.
47. Lindgren H.S., Rylander D., Ohlin K.E., Lundblad M., Cenci M.A. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: relation to dose and route of administration. Behav. Brain Res. 2007, 177:150-159.
48. Lindgren H.S., Ohlin K.E., Cenci M.A. Differential involvement of D1 and D2 dopamine receptors in l-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 2009, 34:2477-2488.
49. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
50. Mai J., Qiu Q., Lin Y.Q., Luo N.S., Zhang H.F., Wen Z.Z., Wang J.F., Yangxin C. Angiotensin II-derived reactive oxygen species promote angiogenesis in human late endothelial progenitor cells through heme oxygenase-1 via ERK1/2 and AKT/PI3K pathways. Inflammation 2014, 37:858-870.
51. Manoonkitiwongsa P.S., Schultz R.L., McCreery D.B., Whitter E.F., Lyden P.D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J. Cereb. Blood Flow Metab. 2004, 24:693-702.
52. Marin C., Rodriguez-Oroz M.C., Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 2006, 197:269-274.
53. Morishita R. Is vascular endothelial growth factor a missing link between hypertension and inflammation?. Hypertension 2004, 44:253-254.
54. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Bjorklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
55. Napoleone E., Cutrone A., Cugino D., Amore C., Di Santo A., Iacoviello L., de Gaetano G., Donati M.B., Lorenzet R. Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells. Thromb. Res. 2012, 129:736-742.
56. Obeso J.A., Olanow C.W., Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 2000, 23:S2-S7.
57. Ohlin K.E., Francardo V., Lindgren H.S., Sillivan S.E., O'Sullivan S.S., Luksik A.S., Vassoler F.M., Lees A.J., Konradi C., Cenci M.A. Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 2011, 134:2339-2357.
58. Ohlin K.E., Sebastianutto I., Adkins C.E., Lundblad C., Lockman P.R., Cenci M.A. Impact of l-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. Neuroimage 2012, 61:228-239.
59. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., De Yebenes J., Gershanik O., Guttman M., Grandas F., Hallett M., Hornykiewicz O., Jenner P., Katzenschlager R., Langston W.J., LeWitt P., Melamed E., Mena M.A., Michel P.P., Mytilineou C., Obeso J.A., Poewe W., Quinn N., Raisman-Vozari R., Rajput A.H., Rascol O., Sampaio C., Stocchi F. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 2004, 19:997-1005.
60. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Van Den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 2001, 28:131-138.
61. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57:168-175.
62. Paxinos G., Watson C. The Rat in Stereotaxic Coordinates 1986, Academic Press, New York.
63. Pelisch N., Hosomi N., Ueno M., Masugata H., Murao K., Hitomi H., Nakano D., Kobori H., Nishiyama A., Kohno M. Systemic candesartan reduces brain angiotensin II via downregulation of brain renin-angiotensin system. Hypertens. Res. 2010, 33:161-164.
64. Pelisch N., Hosomi N., Ueno M., Nakano D., Hitomi H., Mogi M., Shimada K., Kobori H., Horiuchi M., Sakamoto H., Matsumoto M., Kohno M., Nishiyama A. Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am. J. Hypertens. 2011, 24:362-368.
65. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
66. Putterman D.B., Munhall A.C., Kozell L.B., Belknap J.K., Johnson S.W. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2007, 323:277-284.
67. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 2004, 279:1415-1421.
68. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 2000, 342:1484-1491.
69. Rite I., Machado A., Cano J., Venero J.L. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J. Neurochem. 2007, 101:1567-1582.
70. Rodriguez-Pallares J., Parga J.A., Muñoz A., Rey P., Guerra M.J., Labandeira-Garcia J.L. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J. Neurochem. 2007, 103:145-156.
71. Rodriguez-Pallares J., Rey P., Parga J.A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
72. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system. Brain 2012, 135:124-138.
73. Rodriguez-Perez A.I., Dominguez-Meijide A., Lanciego J.L., Guerra M.J., Labandeira-Garcia J.L. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage. Age (Dordr.) 2013, 35:1675-1690.
74. Sarkar C., Chakroborty D., Mitra R.B., Banerjee S., Dasgupta P.S., Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1554-H1560.
75. Sarkar C., Chakroborty D., Chowdhury U.R., Dasgupta P.S., Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res. 2008, 14:2502-2510.
76. Sauter M., Cohen C.D., Wornle M., Mussack T., Ladurner R., Sitter T. ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit. Dial. Int. 2007, 27:167-172.
77. Schallert T., Kozlowski D.A., Humm J.L., Cocke R.R. Use-dependent structural events in recovery of function. Adv. Neurol. 1997, 73:229-238.
78. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:954-963.
79. Shi R.Z., Wang J.C., Huang S.H., Wang X.J., Li Q.P. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp. Cell Res. 2009, 315:10-15.
80. Takahashi S., Nakamura Y., Nishijima T., Sakurai S., Inoue H. Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome. Respir. Med. 2005, 99:1125-1131.
81. Tanaka T., Kanai H., Sekiguchi K., Aihara Y., Yokoyama T., Arai M., Kanda T., Nagai R., Kurabayashi M. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J. Mol. Cell. Cardiol. 2000, 32:1955-1967.
82. Todd R.D., Carl J., Harmon S., O'Malley K.L., Perlmutter J.S. Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J. Neurosci. 1996, 16:7776-7782.
83. Touyz R.M. Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz. J. Med. Biol. Res. 2004, 37:1263-1273.
84. Touyz R.M., Chen X., Tabet F., Yao G., He G., Quinn M.T., Pagano P.J., Schiffrin E.L. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 2002, 90:1205-1213.
85. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc. Res. 2006, 71:226-235.
86. Ushio-Fukai M., Tang Y., Fukai T., Dikalov S.I., Ma Y., Fujimoto M., Quinn M.T., Pagano P.J., Johnson C., Alexander R.W. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ. Res. 2002, 91:1160-1167.
87. Villar-Cheda B., Sousa-Ribeiro D., Rodriguez-Pallares J., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra implications for Parkinson's disease. J. Cereb. Blood Flow Metab. 2009, 29:230-234.
88. Villar-Cheda B., Rodriguez-Pallares J., Valenzuela R., Muñoz A., Guerra M.J., Baltatu O.C., Labandeira-Garcia J.L. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease. Eur. J. Neurosci. 2010, 32:1695-1706.
89. Villar-Cheda B., Valenzuela R., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol. Aging 2012, 33(204):e201-e211.
90. Villar-Cheda B., Dominguez-Meijide A., Valenzuela R., Granado N., Moratalla R., Labandeira-Garcia J.L. Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol. Aging 2014, 35:1726-1738.
91. Wada K., Arai H., Takanashi M., Fukae J., Oizumi H., Yasuda T., Mizuno Y., Mochizuki H. Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. Neuroreport 2006, 17:705-709.
92. Walsh S., Finn D.P., Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011, 175:251-261.
93. Westin J.E., Lindgren H.S., Gardi J., Nyengaard J.R., Brundin P., Mohapel P., Cenci M.A. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia. J. Neurosci. 2006, 26:9448-9461.
94. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
95. Winkler C., Kirik D., Bjorklund A., Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
96. Wosik K., Cayrol R., Dodelet-Devillers A., Berthelet F., Bernard M., Moumdjian R., Bouthillier A., Reudelhuber T.L., Prat A. Angiotensin II controls occludin function and is required for blood-brain barrier maintenance: relevance to multiple sclerosis. J. Neurosci. 2007, 27:9032-9042.
97. Yasuda T., Fukuda-Tani M., Nihira T., Wada K., Hattori N., Mizuno Y., Mochizuki H. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease. Exp. Neurol. 2007, 206:308-317.
98. Yasuhara T., Shingo T., Date I. The potential role of vascular endothelial growth factor in the central nervous system. Rev. Neurosci. 2004, 15:293-307.
99. Yasuhara T., Shingo T., Kobayashi K., Takeuchi A., Yano A., Muraoka K., Matsui T., Miyoshi Y., Hamada H., Date I. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur. J. Neurosci. 2004, 19:1494-1504.
100. Yasuhara T., Shingo T., Muraoka K., wen Ji Y., Kameda M., Takeuchi A., Yano A., Nishio S., Matsui T., Miyoshi Y., Hamada H., Date I. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res. 2005, 1038:1-10.
101. Zalba G., San Jose G., Moreno M.U., Fortuno M.A., Fortuno A., Beaumont F.J., Diez J. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001, 38:1395-1399.
102. Zeng C., Liu Y., Wang Z., He D., Huang L., Yu P., Zheng S., Jones J.E., Asico L.D., Hopfer U., Eisner G.M., Felder R.A., Jose P.A. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ. Res. 2006, 99:494-500.
103. Zhao Q., Ishibashi M., Hiasa K., Tan C., Takeshita A., Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004, 44:264-270.
104. Zhou J., Jezova M., Elkahloun A.G., Saavedra J.M. Angiotensin II AT1 receptor antagonism downregulates stress-related gene expression in brain microvessels from spontaneously hypertensive and normotensive rats. Ann. N. Y. Acad. Sci. 2004, 1018:480-486.
105. Zhou J., Ando H., Macova M., Dou J., Saavedra J.M. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J. Cereb. Blood Flow Metab. 2005, 25:878-886.